San Diego Business Journal

OREXIGEN THERAPEUTICS INC.

CEO and president: Michael Narachi.

Revenue: $4.4 million (2011).

Headquarters: La Jolla.

Year founded: 2002.

Employees: 32.

Stock symbol and exchange: OREX, Nasdaq.

Company description: Bopharmaceutical company focused on the treatment of obesity. Its lead product candidate, Contrave, has completed phase 3 clinical trials.

Key factors for success: Tapping expertise; using contract research organizations; identifying possible path to FDA approval and pursuing it; and receiving investor support.

Although Arena Pharmaceuticals Inc...